title: Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013.
abstract: The Canadian Network for Mood and Anxiety Treatments published guidelines for the management of bipolar disorder in 2005, with updates in 2007 and 2009. This third update, in conjunction with the International Society for Bipolar Disorders, reviews new evidence and is designed to be used in conjunction with the previous publications.The recommendations for the management of acute mania remain largely unchanged. Lithium, valproate, and several atypical antipsychotic agents continue to be first-line treatments for acute mania. Monotherapy with asenapine, paliperidone extended release (ER), and divalproex ER, as well as adjunctive asenapine, have been added as first-line options.For the management of bipolar depression, lithium, lamotrigine, and quetiapine monotherapy, as well as olanzapine plus selective serotonin reuptake inhibitor (SSRI), and lithium or divalproex plus SSRI/bupropion remain first-line options. Lurasidone monotherapy and the combination of lurasidone or lamotrigine plus lithium or divalproex have been added as a second-line options. Ziprasidone alone or as adjunctive therapy, and adjunctive levetiracetam have been added as not-recommended options for the treatment of bipolar depression. Lithium, lamotrigine, valproate, olanzapine, quetiapine, aripiprazole, risperidone long-acting injection, and adjunctive ziprasidone continue to be first-line options for maintenance treatment of bipolar disorder. Asenapine alone or as adjunctive therapy have been added as third-line options.
authors.affiliation: Department of Psychiatry, University of British Columbia, Vancouver, BC, Canada. yatham@interchange.ubc.ca
authors.forename: Lakshmi N
authors.initials: LN
authors.lastname: Yatham
authors.forename: Sidney H
authors.initials: SH
authors.lastname: Kennedy
authors.forename: Sagar V
authors.initials: SV
authors.lastname: Parikh
authors.forename: Ayal
authors.initials: A
authors.lastname: Schaffer
authors.forename: Serge
authors.initials: S
authors.lastname: Beaulieu
authors.forename: Martin
authors.initials: M
authors.lastname: Alda
authors.forename: Claire
authors.initials: C
authors.lastname: O'Donovan
authors.forename: Glenda
authors.initials: G
authors.lastname: Macqueen
authors.forename: Roger S
authors.initials: RS
authors.lastname: McIntyre
authors.forename: Verinder
authors.initials: V
authors.lastname: Sharma
authors.forename: Arun
authors.initials: A
authors.lastname: Ravindran
authors.forename: L Trevor
authors.initials: LT
authors.lastname: Young
authors.forename: Roumen
authors.initials: R
authors.lastname: Milev
authors.forename: David J
authors.initials: DJ
authors.lastname: Bond
authors.forename: Benicio N
authors.initials: BN
authors.lastname: Frey
authors.forename: Benjamin I
authors.initials: BI
authors.lastname: Goldstein
authors.forename: Beny
authors.initials: B
authors.lastname: Lafer
authors.forename: Boris
authors.initials: B
authors.lastname: Birmaher
authors.forename: Kyooseob
authors.initials: K
authors.lastname: Ha
authors.forename: Willem A
authors.initials: WA
authors.lastname: Nolen
authors.forename: Michael
authors.initials: M
authors.lastname: Berk
mesh_terms: D014151:Anti-Anxiety Agents / Q000627:therapeutic use*; D001714:Bipolar Disorder / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology* / Q000523:psychology; D002170:Canada; D017408:Guidelines as Topic / Q000592:standards*; D006801:Humans
chemical_list: D014151:Anti-Anxiety Agents